A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Cynthia Sirard, MD
Chief Medical Officer
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
48 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Charité Universitätsmedizin Berlin
Berlin, Germany
- Institut Fur Klinisch Onkologische Forschung Am Krankenhaus Nordwest
Frankfurt, Germany
- Hämatologisch-Onkologische Praxis Eppendorf (hope)
Hamburg, Germany
- Universitatsklinikum Heidelberg
Heidelberg, Germany
- Slk-Kliniken
Heilbronn, Germany
- Studienzentrum Onkologie Ravensburg
Ravensburg, Germany
- Caritas Klinikum Saarbrücken St. Theresia
Saarbrücken, Germany
- Cha Bundang Medical Center
Seongnam-si, Gyeonggi-do, South Korea
- Korea University Ansan Hospital
Ansan-si, South Korea
- Hallym University Sacred Heart Hospital
Anyang, South Korea
- Dong-A University Hospital
Busan, South Korea
- National Cancer Center
Goyang, South Korea
- Gachon University Gil Medical Center
Incheon, South Korea
- Inha University Hospital
Incheon, South Korea
- Seoul National University Bundang Hospital
Seongnam, South Korea
- Asan Medical Center
Seoul, South Korea
- Boramae Hospital Snu
Seoul, South Korea
- Hanyang University Hospital
Seoul, South Korea
- Korea University Anam Hospital
Seoul, South Korea
- Korea University Guro Hospital
Seoul, South Korea
- Samsung Medical Center
Seoul, South Korea
- Seoul National University Hospital
Seoul, South Korea
- Severance Hospital, Yonsei University Health System
Seoul, South Korea
- the Catholic University of Korea St. Mary'S Hospital
Seoul, South Korea
- the Catholic University of Korea St. Vincent'S Hospital
Suwon, South Korea
- Mayo Clinic Cancer Center
Phoenix, Arizona, United States
- University of Arizona
Tucson, Arizona, United States
- City of Hope
Duarte, California, United States
- the Angeles Clinic Research Institute - A Cedars-Sinai Affiliate
Los Angeles, California, United States
- Ucla
Los Angeles, California, United States
- University of Southern California
Los Angeles, California, United States
- Hoag Memorial Hospital Presbyterian
Newport Beach, California, United States
- Chao Family Comprehensive Cancer Center, University of California, Irvine
Orange, California, United States
- University of California San Francisco
San Francisco, California, United States
- Mayo Clinic Florida
Jacksonville, Florida, United States
- Adventhealth Cancer Institute
Orlando, Florida, United States
- Northwestern University Robert H. Lurie Comprehensive Cancer Center
Chicago, Illinois, United States
- University of Chicago
Chicago, Illinois, United States
- Pontchartrain Cancer Center
Covington, Louisiana, United States
- Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 29 Jul 2020
- Primary completion
- 31 Mar 2025
- Completion
- 31 Mar 2025
- Last update posted
- 9 Oct 2025
- Registered enrollment
- 247
- Registry id
- NCT04363801
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.